Clinical trialNo phase (not a drug trial)No longer available
Expanded Access RBS2418 Treatment
Expanded Access to RBS2418 for an Individual Patient With Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- No phase (not a drug trial)
- Status
- No longer available
- Study type
- Expanded access
- Sites
- 0
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 21 February 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418